A Bombesin Immunoreactive Peptidein Milk

Total Page:16

File Type:pdf, Size:1020Kb

A Bombesin Immunoreactive Peptidein Milk Proc. Natl. Acad. Sci. USA Vol. 81, pp. 578-582, January 1984 Medical Sciences A bombesin immunoreactive peptide in milk (radioinimunoassay/gel filtration/high-performance liquid chromatography) GLORIA D. JAHNKE* AND LAWRENCE H. LAZARUSt Peptide Neurochemistry Workgroup, Laboratory of Behavioral and Neurological Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 Communicated by George H. Hitchings, September 19, 1983 ABSTRACT Immunoreactivity to the amphibian peptide tains peptide and steroid hormones (32), prostaglandins (33), bombesin was found in instant nonfat dry milk (ca. 0.7 ng/ml) morphine (34), melatonin (35), and immunoglobulins (36) in and in the whey of whole or skim bovine milk (ca. 1.2 ng/ml) addition to a growth factor and enzymes (37, 38). even after ultracentrifugation. The soluble immunoreactivity Moreover, the peptide hormones and the growth factor re- was associated with a peptide exhibiting the following charac- tain their biological activities in milk (37, 39, 40) and, when teristics: (i) parallel displacement in an immunoassay using an ingested by the neonate, appear intact in plasma (35, 39-42). antiserum recognizing bombesin amino acid residues 5-8; (ii) Thus, considering the coincidence between the action of am- separation from both gastrin-releasing peptide and amphibian phibian bombesin and milk on hormone peptide levels, we bombesin by gel filtration-the approximate Mr was 3,200; sought to determine whether milk could be a source of a (iii) denaturation in urea, reduction by dithiothreitol, and bombesin-related peptide. In this communication, we pro- acetylation by iodoacetamide had no effect on its elution profile vide evidence that milk contains bombesin immunoreactivity by gel-filtration chromatography and the aggregation of added that is distinct from both GRP and amphibian bombesin and bombesin to milk proteins or peptides was not observed; (iv) is associated with a heat-stable, protease-sensitive peptide reversed-phase HPLC separated milk immunoreactivity from with a Mr of about 3,200. gastrin-releasing peptide and bombesin; (v) digestion by tryp- sin yielded a smaller immunoreactive peptide fragment, MATERIALS AND METHODS whereas nearly all immunoreactivity was lost by treatment and whole milk from several differ- with a-chymotrypsin; and (vi) the level of immunoreactivity Milk. Pasteurized skim milk is an ent local dairies were purchased 5-7 days before the expira- was unaffected by boiling. These data show that tion date. Instant nonfat dry milk was the product of several exogenous source of bombesin-like immunoreactivity,, which reconstituted according to the manu- may account for the increase of gastric acid and gastrointesti- major companies and of milk. facturer. A portion (200 ml) was acidified to pH 2.3 with for- nal hormone levels after the consumption mic acid and brought to 80% in cold acetone according to Brown et al. (2) for the extraction of bombesin from plasma. Immunoreactivity to bombesin, an amphibian tetradecapep- The extract was clarified by centrifugation (20,000 x g for 30 tide (1), is distributed throughout mammalian tissues (2-5). min at 40C), and the supernatant was decreased in volume Bombesin administered through intraperitoneal or intracis- under vacuum and clarified again by centrifugation. The vol- ternal injection or intravenous infusion elicits diverse phys- ume of this supernatant was then further decreased under iological effects in a variety of animal species, including hu- nitrogen at 500C. mans (6-12). These effects include hypertension (1, 6, 13, Radioimmunoassay (RIA). [Tyr8]Bombesin and GRP were 14), satiety (for review, see ref. 15), change in sugar metabo- iodinated every 4-6 weeks as described (43). The production lism (16, 17), hypothermia (18), modulation of the level of of the antiserum to bombesin has been described (44). Op- many gastrointestinal-associated peptide hormones (6-12, timum RIA conditions, which were systematically deter- 19-24), and increase of gastric acid secretion (7, 10, 13, 14, mined, are as follows: 0.1 M sodium cacodylate, pH 5.6/bo- 19, 20). Bombesin also releases both gastrin and gastric acid in vine serum albumin (5 mg/ml)/125I-labeled [Tyr8]bombesin from isolated fundic mucosa (25) and acts as a spasmogen (or GRP) (2,500 cpm)/antiserum BM-XII-165-4 (final dilu- isolated smooth muscle preparations (1, 6, 13, 14, 26). In tion, 1:4,000)/standard or test solution in a total vol of 100 keeping with these observations, specific bombesin-contain- ,ul. Nonionic (Triton X-100, Nonidet P-40) and ionic (sodium ing cells were identified by immunohistochemistry in the lauryl sulfate) detergents above 0.1% and chaotropic agents gastric mucosa (27). Furthermore, an endogenous bombesin- (urea, guanidine HCl) above 0.1 M substantially decreased like gastrin-releasing peptide (GRP) was isolated from mam- binding of the labeled peptide to the antibody. The antibody- malian non-antral tissue (28), and its pharmacological mode bound ligand was precipitated after a 16-18 hr incubation at of action is similar to bombesin at comparable dosages (17, 40C with 1.0 ml of 15.6% polyethylene glycol 8000 in the 24, 27, 29). presence of 0.05 ml of outdated human plasma (44). Based Infusion of bombesin brings about an increase above basal on the relative crossreactivity of sequence-related peptides plasma levels of the peptide hormones insulin, gastrin-inhib- (Table 1) this antiserum apparently recognizes the mid-re- iting peptide, neurotensin, pancreatic polypeptide, gastrin, gion of bombesin (residues 5-8). The oxidation of trypto- motilin, enteroglucagon, secretin, and growth hormone (6- phan-8 also decreased binding of bombesin to the antibody. 14, 19-23); these are the same peptides that increase after Alytesin, used as the amphibian analogue of chicken proven- the consumption of milk in human neonates (for review, see tricular GRP (45), and porcine GRP produced nonparallel ref. 30). Bombesin also increases the levels of somatostatin displacement curves relative to bombesin (Fig. 1). Other (22) and prolactin (9). Milk, which is a rich nutrient meal, is known peptides, such as physalaemin, neurotensin, and bra- known for its caloric components (protein, carbohydrates, it also con- fat) and micronutrients (vitamins, minerals) (31); Abbreviations: RIA, radioimmunoassay; GRP, gastrin-releasing peptide (bombesin-like heptacosapeptide). The publication costs of this article were defrayed in part by page charge *Present address: School of Veterinary Medicine, North Carolina payment. This article must therefore be hereby marked "advertisement" State University, Raleigh, NC 27650. in accordance with 18 U.S.C. §1734 solely to indicate this fact. tTo whom reprint requests should be addressed. 578 Downloaded by guest on September 24, 2021 Medical Sciences: Jahnke and Lazarus Proc. Natl. Acad Sci. USA 81 (1984) 579 Table 1. Specificity of antiserum to bombesin Relative molar Peptide Structure crossreactivity Bombesin pGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 1.00 [Tyr']Bombesin Tyr 1.00 [Tyr8]Bombesin Tyr 0.73 [Tyr5]Bombesin-(5-14) Tyr 0.18* Alytesin Gly Thr 2.62 ± 0.87 (5)* GRPt -Met-Tyr-Pro-Arg His 1.34 ± 0.14 (6)* Ranatensin pGlu-Val-Pro Phe 0.0003 Litorin pGlu Phe 0.0008 Substance P Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly 0.000003 Peptide concentrations ranged from 0.1 fmol/ml to 1.3 nmol/ml. Relative molar crossreactivity is based on 50% displacement point from log- logit plots; n value in parentheses when more than two repetitions. *Nonparallel displacement curves. tThe sequence of porcine GRP preceding the bombesin-like region is Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr-Val-Leu-Ala-Lys- (28). dykinin failed to displace the radioligand at concentrations of RESULTS 10 nmol/ml. Quantitation. Whole, skim, and reconstituted dry bovine Chromatography. Gel filtration of milk extracts used Bio- milk, whey, and the acid/acetone extract produced displace- Gel P-4 (100-200 mesh) columns (1.5 x 94 cm) equilibrated ment curves in the RIA parallel to that of bombesin (Fig. 2). with 0.1 M formic acid. The immunoreactive peak from this To rule out the possibility that the bombesin immunoreactiv- column fractionation was concentrated, absorbed onto and ity could be extracted by formic acid from a bacterial con- eluted from a Sep-Pak with methanol, and injected onto a taminant [Escherichia coli has been found to contain insu- reversed-phase HPLC system [Laboratory Data Control unit lin (47)], lipids, or leukocytes (38), milk was centrifuged fitted with a Rheodyne injector with a Spherisorb ODS 5-gm (100,000 x g for 30 min at 4°C) before assaying; the displace- (250 x 4.6 mm) or a Bio-Sil ODS 5-,um (150 x 4 mm, end- ment curve of the resultant whey was superimposable on capped) column]. The samples were eluted with linear gradi- that of the original milk sample (Fig. 2). The level of bombe- ents of either 0-60% or 0-80% acetonitrile (vol/vol)/0.01 M sin immunoreactivity in whole and skim milk was similar, trifluoroacetic acid, pH 2.3. Fractions were collected at 1- about 1.2 ng/ml in bombesin equivalents, and that in recon- min intervals at a flow rate of 1.0 ml/min; a 5-min delay was stituted dry milk was about half of this amount (Table 2). The used before initiating the gradient. To eliminate any possible total amount of immunoreactivity recovered in the acetone contamination of the equipment, blank gradients were as- extract, however, was only 17.5 ± 6.9% (n = 4). The boiling sayed by RIA as described (44). As a further precaution, the of whole milk to inhibit proteases that could interfere with injector and column were flushed with acetonitrile between the RIA (48) gave identical results. The recovery of 6.2 pmol analyses and washed daily with water, acetonitrile, metha- of bombesin added to whole milk was 90.3 ± 20.6% (n = 4).
Recommended publications
  • Fast Cancer Uptake of 99Mtc-Labelled Bombesin (99Mtc BN1)
    in vivo 19: 1071-1076 (2005) Fast Cancer Uptake of 99mTc-labelled Bombesin (99mTc BN1) F. SCOPINARO1, G. P. DI SANTO1, A. TOFANI1, R. MASSARI2, C. TROTTA2, M. RAGONE3, S. ARCHIMANDRITIS4 and A.D. VARVARIGOU5 1Department of Scienze Radiologiche and 4Faculty of Engineering, University “La Sapienza”, Rome; 2University Hospital “San Andrea”, Rome; 3Li-Tech and ISIB-CNR, Udine and Rome, Italy; 5National Research Center,"Demokritos", Athens, Greece Abstract. In human blood, breakdown of gastrin-releasing show istant action because BN receptors (BNRs) and BNR peptide and other bombesin-related peptides occurs in less than subtypes (BNS) are the same in different tissues; however, 15 min. This quick enzymatic cleavage might impair the the action of the above peptides is prevented by their rapid diagnostic use of labelled bombesin (BN). 99mTc-labelled breakdown in the serum. bombesin (99mTc BN1) was injected intravenously and BN and BN-related peptides are neuro-hormones and dynamic uptake data were acquired for diagnosing 26 cancers neurotransmitters; the three well known human BNS show a of different origin: 15 breast, 3 prostate, 5 colo-rectal, 1 number of functions in the central nervous system (4, 5). pancreas, 2 small cell lung cancers and 1 gastrinoma. BNS is also expressed in several foetal and adult tissues, Background subtracted tumour uptake data were plotted where BN-related peptides act as releasing factors, against time and fitted with known mathematical functions. morphogens and growth factors (6-8). Finally, BN-related Twenty-three out of 26 cancers showed rapid increase of peptides, whose paracrine and autocrine production has radioactivity followed by a radioactivity plateau, with some already been mentioned, act as mitogens, growth and anti- oscillations around the average plateau value.
    [Show full text]
  • Vasoactive Intestinal Peptide Inhibits Human Small-Cell Lung Cancer Proliferation in Vitro and in Vivo (Neuropeptides͞camp͞cell Culture͞athymic Nude Mice)
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 14373–14378, November 1998 Medical Sciences Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo (neuropeptidesycAMPycell cultureyathymic nude mice) KANAME MARUNO*, AFAF ABSOOD†, AND SAMI I. SAID‡ Department of Medicine, Northport Veterans Affairs Medical Center Stony Brook, NY 11768-2290, and State University of New York, Health Sciences Center 17-040, Stony Brook, NY 11794-8172 Communicated by Susan E. Leeman, Boston University School of Medicine, Boston, MA, September 23, 1998 (received for review March 15, 1998) ABSTRACT Small-cell lung carcinoma (SCLC) is an ag- cell lines (7, 8). The cells were maintained in RPMI medium gressive, rapidly growing and metastasizing, and highly fatal 1640 containing 10 nM hydrocortisone, 5.0 mgyml insulin, 10 neoplasm. We report that vasoactive intestinal peptide inhib- mgyml transferrin, 10 nM 17b-estradiol, 30 nM sodium selen- its the proliferation of SCLC cells in culture and dramatically ite, 100 unitsyml penicillin, and 100 mgyml streptomycin suppresses the growth of SCLC tumor-cell implants in athy- (HITES medium; ref. 9). As a control, the SCLC cell line mic nude mice. In both cases, the inhibition was mediated NCI-H128 (American Type Culture Collection), which lacks apparently by a cAMP-dependent mechanism, because the VIP receptors (10), was also tested. The cells were incubated inhibition was enhanced by the adenylate cyclase activator in tissue-culture flasks in a humidified atmosphere of 5% CO2 forskolin and the phosphodiesterase inhibitor 3-isobutyl-1- in air at 37°C and grown as floating cell aggregates.
    [Show full text]
  • Secretin and Autism: a Clue but Not a Cure
    SCIENCE & MEDICINE Secretin and Autism: A Clue But Not a Cure by Clarence E. Schutt, Ph.D. he world of autism has been shaken by NBC’s broadcast connections could not be found. on Dateline of a film segment documenting the effect of Tsecretin on restoring speech and sociability to autistic chil- The answer was provided nearly one hundred years ago by dren. At first blush, it seems unlikely that an intestinal hormone Bayless and Starling, who discovered that it is not nerve signals, regulating bicarbonate levels in the stomach in response to a but rather a novel substance that stimulates secretion from the good meal might influence the language centers of the brain so cells forming the intestinal mucosa. They called this substance profoundly. However, recent discoveries in neurobiology sug- “secretin.” They suggested that there could be many such cir- gest several ways of thinking about the secretin-autism connec- culating substances, or molecules, and they named them “hor- tion that could lead to the breakthroughs we dream about. mones” based on the Greek verb meaning “to excite”. As a parent with more than a decade of experience in consider- A simple analogy might help. If the body is regarded as a commu- ing a steady stream of claims of successful treatments, and as a nity of mutual service providers—the heart and muscles are the pri- scientist who believes that autism is a neurobiological disorder, I mary engines of movement, the stomach breaks down foods for have learned to temper my hopes about specific treatments by distribution, the liver detoxifies, and so on—then the need for a sys- seeing if I could construct plausible neurobiological mechanisms tem of messages conveyed by the blood becomes clear.
    [Show full text]
  • Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases Achim Fleischmann, Ursula Läderach, Helmut Friess, Markus W
    0023-6837/00/8012-1807$03.00/0 LABORATORY INVESTIGATION Vol. 80, No. 12, p. 1807, 2000 Copyright © 2000 by The United States and Canadian Academy of Pathology, Inc. Printed in U.S.A. Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases Achim Fleischmann, Ursula Läderach, Helmut Friess, Markus W. Buechler, and Jean Claude Reubi Division of Cell Biology and Experimental Cancer Research (AF, UL, JCR), Institute of Pathology, University of Berne, and Department of Visceral and Transplantation Surgery (HF, MWB), Inselspital, University of Berne, Berne, Switzerland SUMMARY: Overexpression of receptors for regulatory peptides in various human diseases is reportedly of clinical interest. Among these peptides, bombesin and gastrin-releasing peptide (GRP) have been shown to play a physiological and pathophysiological role in pancreatic tissues. Our aim has been to localize bombesin receptors in the human diseased pancreas to identify potential clinical applications of bombesin analogs in this tissue. The presence of bombesin receptor subtypes has been evaluated in specimens of human pancreatic tissues with chronic pancreatitis (n ϭ 23) and ductal pancreatic carcinoma (n ϭ 29) with in vitro receptor autoradiography on tissue sections incubated with 125I-[Tyr4]-bombesin or the universal ligand 125I-[D-Tyr6, ␤-Ala11, Phe13, Nle14]-bombesin(6–14) as radioligands and displaced by subtype-selective bombesin receptor agonists and antagonists. GRP receptors were identified in the pancreatic exocrine parenchyma in 17 of 20 cases with chronic pancreatitis. No measurable bombesin receptors were found in the tumor tissue of ductal pancreatic carcinomas, however, GRP receptors were detected in a subset of peritumoral small veins in 19 of 29 samples.
    [Show full text]
  • Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors
    Journal of Nuclear Medicine, published on September 4, 2014 as doi:10.2967/jnumed.114.142000 CONTINUING EDUCATION Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors Clément Morgat1–3, Anil Kumar Mishra2–4, Raunak Varshney4, Michèle Allard1,2,5, Philippe Fernandez1–3, and Elif Hindié1–3 1CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France; 2University of Bordeaux, INCIA, UMR 5287, Talence, France; 3CNRS, INCIA, UMR 5287, Talence, France; 4Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, DRDO, New Delhi, India; and 5EPHE, Bordeaux, France Learning Objectives: On successful completion of this activity, participants should be able to list and discuss (1) the presence of bombesin receptors, neurotensin receptors, or neuropeptide-Y receptors in some major tumors; (2) the perspectives offered by radiolabeled peptides targeting these receptors for imaging and therapy; and (3) the choice between agonists and antagonists for tumor targeting and the relevance of various PET radionuclides for molecular imaging. Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through October 2017.
    [Show full text]
  • Small Cell Lung Cancer Cells: Stimulation by Multiple Neuropeptides and Inhibition by Broad Spectrum Antagonists
    SMALL CELL LUNG CANCER CELLS: STIMULATION BY MULTIPLE NEUROPEPTIDES AND INHIBITION BY BROAD SPECTRUM ANTAGONISTS. A thesis submitted for the degree of Doctor of Philosophy in the University of London by TARIQJ. SETHI July 1993 Growth Regulation Laboratory Department of Cell Biology Imperial Cancer Research Fund University College London London ProQuest Number: 10017254 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10017254 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Human small cell lung cancer (SCLC) constitutes 25% of lung cancers and follows an aggressive clinical course. SCLC is characterised by the presence of intracytoplasmic neurosecretory granules and by its ability to secrete many hormones and neuropeptides. Only bombesin-like peptides, which include gastrin-releasing peptide (GRP), have been shown to act as autocrine growth factors for certain SCLC cell lines. This thesis focused on other neuropeptides and particularly their ability to mediate SCLC growth. The neuropeptides bradykinin, cholecystokinin (CCK), GRP, neurotensin and vasopressin at nanomolar concentrations stimulated an increase in the intracellular concentration of calcium ([Ca^+Jj), inositol phosphate hydrolysis, and increased colony formation in semi-solid medium in responsive SCLC cell lines.
    [Show full text]
  • Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease
    cells Review Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease Chongxu Zhang 1, Tengjiao Cui 1, Renzhi Cai 1, Medhi Wangpaichitr 1, Mehdi Mirsaeidi 1,2 , Andrew V. Schally 1,2,3 and Robert M. Jackson 1,2,* 1 Research Service, Miami VAHS, Miami, FL 33125, USA; [email protected] (C.Z.); [email protected] (T.C.); [email protected] (R.C.); [email protected] (M.W.); [email protected] (M.M.); [email protected] (A.V.S.) 2 Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33101, USA 3 Department of Pathology and Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33101, USA * Correspondence: [email protected]; Tel.: +305-575-3548 or +305-632-2687 Received: 25 August 2020; Accepted: 17 October 2020; Published: 21 October 2020 Abstract: Growth hormone-releasing hormone (GHRH) is secreted primarily from the hypothalamus, but other tissues, including the lungs, produce it locally. GHRH stimulates the release and secretion of growth hormone (GH) by the pituitary and regulates the production of GH and hepatic insulin-like growth factor-1 (IGF-1). Pituitary-type GHRH-receptors (GHRH-R) are expressed in human lungs, indicating that GHRH or GH could participate in lung development, growth, and repair. GHRH-R antagonists (i.e., synthetic peptides), which we have tested in various models, exert growth-inhibitory effects in lung cancer cells in vitro and in vivo in addition to having anti-inflammatory, anti-oxidative, and pro-apoptotic effects. One antagonist of the GHRH-R used in recent studies reviewed here, MIA-602, lessens both inflammation and fibrosis in a mouse model of bleomycin lung injury.
    [Show full text]
  • Inhibition of Gastrin Release by Secretin Is Mediated by Somatostatin in Cultured Rat Antral Mucosa
    Inhibition of gastrin release by secretin is mediated by somatostatin in cultured rat antral mucosa. M M Wolfe, … , G M Reel, J E McGuigan J Clin Invest. 1983;72(5):1586-1593. https://doi.org/10.1172/JCI111117. Research Article Somatostatin-containing cells have been shown to be in close anatomic proximity to gastrin-producing cells in rat antral mucosa. The present studies were directed to examine the effect of secretin on carbachol-stimulated gastrin release and to assess the potential role of somatostatin in mediating this effect. Rat antral mucosa was cultured at 37 degrees C in Krebs-Henseleit buffer, pH 7.4, gassed with 95% O2-5% CO2. After 1 h the culture medium was decanted and mucosal gastrin and somatostatin were extracted. Carbachol (2.5 X 10(-6) M) in the culture medium increased gastrin level in the medium from 14.1 +/- 2.5 to 26.9 +/- 3.0 ng/mg tissue protein (P less than 0.02), and decreased somatostatin-like immunoreactivity in the medium from 1.91 +/- 0.28 to 0.62 +/- 0.12 ng/mg (P less than 0.01) and extracted mucosal somatostatin-like immunoreactivity from 2.60 +/- 0.30 to 1.52 +/- 0.16 ng/mg (P less than 0.001). Rat antral mucosa was then cultured in the presence of secretin to determine its effect on carbachol-stimulated gastrin release. Inclusion of secretin (10(-9)-10(-7) M) inhibited significantly carbachol-stimulated gastrin release into the medium, decreasing gastrin from 26.9 +/- 3.0 to 13.6 +/- 3.2 ng/mg (10(-9) M secretin) (P less than 0.05), to 11.9 +/- 1.7 ng/mg (10(-8) secretin) (P less than 0.02), and to 10.8 +/- 4.0 ng/mg (10(-7) M secretin) (P less than […] Find the latest version: https://jci.me/111117/pdf Inhibition of Gastrin Release by Secretin Is Mediated by Somatostatin in Cultured Rat Antral Mucosa M.
    [Show full text]
  • Occurrence of Bombesin and Alytesin in Extracts of the Skin of Three
    Br. J. Pharmac. (1972), 45, 333-348. Occurrence of bombesin and alytesin in extracts of the skin of three European discoglossid frogs and pharmacological actions of bombesin on extravascular smooth muscle V. ERSPAMER, G. FALCONIERI ERSPAMER, M. INSELVINI AND L. NEGRI Institute of Medical Pharmacology I, University of Rome, Rome, Italy Summary 1. Methanol extracts of the skin of Bombina bombina and Bombina variegata variegata, two European discoglossid frogs, contain an active tetradecapeptide, bombesin. Alytesin, a tetradecapeptide strictly related to bombesin is present in extracts of the skin of Alytes obstetricans, another European discoglossid frog. The American frog Rana pipiens, contains in its skin ranatensin, an endecapeptide related to bombesin and alytesin. 2. Passage of crude skin extracts of Bombina through a column of alumina yields eluates which may be considered free of other peptide contaminants and are suitable for the isolation of bombesin in a pure form. 3. Bombesin has a stimulant action on several preparations of intestinal, uterine and urinary tract smooth muscle. Sometimes the effect is easily repeatable and shows a fair proportionality to the dose, but at other times a prompt and intense tachyphylaxis is observed. Other smooth muscle prepara- tions are poorly sensitive or insensitive to bombesin. The rat uterus, the kitten small intestine, the guinea-pig colon and the rat urinary bladder may be used for the quantitative bioassay of bombesin. 4. Bombesin-like peptides may easily be distinguished from all other naturally occurring peptides by parallel assay. They constitute a new group of active peptides possessing a peculiar spectrum of activity. Introduction Methanol extracts of the skin of the two European discoglossid frogs Bombina bombina and Bombina variegata variegata contain a principle which displays a number of pharmacological actions on vascular and extravascular smooth muscle and on gastric secretion (Erspamer, Falconieri Erspamer & Inselvini, 1970; Melchiorri, Sopranzi & Erspamer, 1971).
    [Show full text]
  • Secretin/Vasoactive Intestinal Peptide-Stimulated Secretion of Bombesin/ Gastrin Releasing Peptide from Human Small Cell Carcinoma of the Lung1
    ICANCER RESEARCH 46, 1214-1218, March 1986] Secretin/Vasoactive Intestinal Peptide-stimulated Secretion of Bombesin/ Gastrin Releasing Peptide from Human Small Cell Carcinoma of the Lung1 Louis Y. Korman,2 Desmond N. Carney, Marc L. Citron, and Terry W. Moody Medica/ Service (151W), Veterans Administration Medical Center, Washington, DC 20422 [L. Y.K., M.L.C.]; Department of Medicine and Biochemistry George Washington University School of Medicine, Washington, DC 20037 [T. W. M.¡;and National Cancer Institute-Navy Medical Oncology Branch National Cancer Institute and National Naval Medical Center, Bethesda, Maryland [D. N. C.¡ ABSTRACT autocrine factor for SCCL (12) growth. We studied the mecha nism of BLI secretion in several SCCL cell lines by examining Bombesin/gastrin releasing peptide-like immunoreactivity (BLI) the action of agents that increase intracellular cAMP. is found in the majority of small cell carcinoma of the lung (SCCL) Because of the results of these in vitro studies and the fact cell lines examined. Because BLI is present in high concentration that secretin stimulates hormone release in patients with gastrin in SCCL we studied the mechanism of BLI secretion from several producing tumors (Zollinger-Ellison syndrome), we examined the SCCL cell lines and in patients with SCCL. In cell line NCI-H345 action of i.v. secretin infusion on plasma BLI levels in several the structurally related polypeptide hormones secretin, vasoac- patients with SCCL, non-SCCL lung tumors, and patients with tive intestinal peptide, and peptide histidine isoleucine as well as theophylline, a phosphodiesterase inhibitor, N6,O2'-dibutyryl out any cancer. cyclic adenosine 3':5'-monophosphate, a cyclic nucleotide ana logue, increased BLI release by 16-120% and cyclic adenosine MATERIALS AND METHODS 3':5'-monophosphate by 36-350%.
    [Show full text]
  • The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation
    biomedicines Review The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation Haiyan Zheng 1, Ji Yeon Lim 1, Jae Young Seong 1 and Sun Wook Hwang 1,2,* 1 Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Korea; [email protected] (H.Z.); [email protected] (J.Y.L.); [email protected] (J.Y.S.) 2 Department of Physiology, College of Medicine, Korea University, Seoul 02841, Korea * Correspondence: [email protected]; Tel.: +82-2-2286-1204; Fax: +82-2-925-5492 Received: 12 November 2020; Accepted: 15 December 2020; Published: 17 December 2020 Abstract: Peripheral nociceptors and their synaptic partners utilize neuropeptides for signal transmission. Such communication tunes the excitatory and inhibitory function of nociceptor-based circuits, eventually contributing to pain modulation. Corticotropin-releasing hormone (CRH) is the initiator hormone for the conventional hypothalamic-pituitary-adrenal axis, preparing our body for stress insults. Although knowledge of the expression and functional profiles of CRH and its receptors and the outcomes of their interactions has been actively accumulating for many brain regions, those for nociceptors are still under gradual investigation. Currently, based on the evidence of their expressions in nociceptors and their neighboring components, several hypotheses for possible pain modulations are emerging. Here we overview the historical attention to CRH and its receptors on the peripheral nociception and the recent increases in information regarding their roles in tuning pain signals. We also briefly contemplate the possibility that the stress-response paradigm can be locally intrapolated into intercellular communication that is driven by nociceptor neurons.
    [Show full text]
  • Synthesis, Characterization and Evaluation of Peptide Nanostructures for Biomedical Applications
    molecules Review Synthesis, Characterization and Evaluation of Peptide Nanostructures for Biomedical Applications Fanny d’Orlyé, Laura Trapiella-Alfonso , Camille Lescot, Marie Pinvidic, Bich-Thuy Doan and Anne Varenne * Chimie ParisTech PSL, CNRS 8060, Institute of Chemistry for Life and Health (i-CLeHS), 75005 Paris, France; [email protected] (F.d.); [email protected] (L.T.-A.); [email protected] (C.L.); [email protected] (M.P.); [email protected] (B.-T.D.) * Correspondence: [email protected]; Tel.: +33-1-8578-4252 Abstract: There is a challenging need for the development of new alternative nanostructures that can allow the coupling and/or encapsulation of therapeutic/diagnostic molecules while reducing their toxicity and improving their circulation and in-vivo targeting. Among the new materials using natural building blocks, peptides have attracted significant interest because of their simple structure, relative chemical and physical stability, diversity of sequences and forms, their easy functionalization with (bio)molecules and the possibility of synthesizing them in large quantities. A number of them have the ability to self-assemble into nanotubes, -spheres, -vesicles or -rods under mild conditions, which opens up new applications in biology and nanomedicine due to their intrinsic biocompatibility and biodegradability as well as their surface chemical reactivity via amino- and carboxyl groups. In order to obtain nanostructures suitable for biomedical applications, the structure, size, shape and surface chemistry of these nanoplatforms must be optimized. These properties depend directly on Citation: d’Orlyé, F.; the nature and sequence of the amino acids that constitute them.
    [Show full text]